to-BBB's 2B3-101 - A New Treatment Option for Patients with Brain Cancer?
A novel drug for patients with brain cancer, 2B3-101, has shown preliminary positive results. The Dutch biotech to-BBB has developed 2B3-101 and initiated a clinical trial to investigate this new treatment. The Phase I safety results will be presented at the European Cancer Congress 2013 in Amsterdam at the end of September.
“This first clinical trial with 2B3-101 has focused on the safety of this new treatment, yet, promising signs of anti-tumour activity were observed in many of the patients at the higher dose levels tested,” says Dr Dieta Brandsma from the Netherlands Cancer Institute — Antoni van Leeuwenhoek hospital (NKI-AVL).
The preliminary positive results from this clinical trial have warranted further investigation into the efficacy of 2B3-101. Thus, as a next step, four disease groups will be treated in the Phase IIa part of this trial, including patients with recurrent malignant gliomas, and patients with brain metastases from breast cancer, small cell lung cancer or melanomas.
Fredrik Lonnqvist, Chief Medical Officer at to-BBB, adds: “The prognosis for patients with brain cancer is usually poor, and there are very limited treatment options available. Therefore, we are committed to the continued evaluation of 2B3-101, based on the results seen so far.”
Results of this first clinical trial with 2B3-101 will be presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) on the 30 September. The safety of 2B3-101 was investigated both in patients with brain metastases from solid tumours and in patients with recurrent malignant gliomas. Patients that participated in this study were either refractory to standard therapy or unable to receive existing standard therapy. Adverse events reported during the study were all expected, and mainly related to transient bone marrow suppression, skin lesions (hand-foot syndrome) and mild to moderate infusion reactions. No signs of drug-related neurotoxicity and cardiotoxicity were observed. An additional 2B3-101 dose-escalation study in combination with Herceptin is currently also about to be completed, which will allow inclusion of additional HER2+ breast cancer patients with brain metastases in the Phase IIa part of this trial.
The brain is a well-protected organ. The so-called blood–brain barrier selectively allows nutrients to enter the brain, and keeps harmful substances but also most drugs out of the brain. This makes treatment of brain tumours much more challenging compared with treatment of tumours outside the brain. By use of to-BBB’s proprietary G-Technology, the blood-to-brain delivery of drugs is enhanced by using active transport processes at the blood-brain barrier.
The 2B3-101 concept is based on the G-Technology and has previously been evaluated in non-clinical studies with promising results. In these studies, to-BBB has shown that conjugation of glutathione to the tips of pegylated liposomes can provide a five-fold increased delivery of doxorubicin to the brain compared to untargeted liposomes. In addition, treatment with 2B3-101 improved the survival of mice in an experimental model of brain cancer (glioblastoma) by 60%.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance